Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission

Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan

August 9, 2016 6:51 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.80, $0.09 better than the analyst estimate of $0.71. Revenue for the quarter came in at $40.9 million versus the consensus estimate of $40.8 million.

On August 2, 2016, the Board of Directors has approved a share repurchase program, under... More